Refine
Document Type
- Doctoral Thesis (4)
Language
- English (4)
Has Fulltext
- yes (4)
Is part of the Bibliography
- no (4)
Institute
The multistep-processes leading to the formation of tumors have been extensively studied in the past decades, leading to the identification of “hallmarks of cancer”. They are characteristic changes in biological processes that discriminate tumor cells from healthy cells. Increasing knowledge on the molecular structures associated with tumorigenesis allowed their specific inhibition in targeted anti-cancer therapy. However, successful targeted anti-cancer therapy is only available for a limited subset of diseases, so the continuous investigation of tumorigenic mechanisms is required to tackle the immense diversity of neoplastic entities.
AVEN and FUSE binding protein 1 (FUBP1) display the ability to regulate apoptosis and cell cycle progression. Thus, the proteins are associated with hallmarks of cancer (resisting cell death and uncontrolled proliferation). Indeed, aberrant expression of AVEN and FUBP1 could be demonstrated in multiple cancers. In contrast, there is only little knowledge on the physiological function of AVEN and FUBP1. The lack of knowledge results in part from the embryonic lethality of the homozygous knockout of Aven and Fubp1 in mouse models, limiting the gain of information by analyzing these animals.
In this study, I generated conditional Aven and Fubp1 knockout mice to investigate their physiological function.
By analyzing reporter mice expressing β-galactosidase under the control of the endogenous Aven promoter, I identified Aven promoter activity to be both tissue- and cell type-specific and dependent on the developmental stage. Detecting apoptotic cell death by immunohistochemistry did not reveal increased apoptosis in Aven knockout mice, suggesting a functional role of AVEN besides apoptosis inhibition during embryogenesis.
Basing on the significant Aven promoter activity detected in the adult brain and in the mammary gland, I generated and characterized conditional Aven knockout mice with Aven deletion restricted to cells within the brain or the mammary gland. AVEN depletion in these tissues was not embryonic lethal and the affected tissues displayed a normal histology.
Since aberrant Aven expression had been associated with hematologic malignancies, I also analyzed mice with an Aven knockout in the hematopoietic system. Depletion of AVEN in the blood cells had no effect on hematopoietic stem and progenitor cell frequencies. Consequently, AVEN seems to be dispensable for the maintenance and differentiation of stem, progenitor and mature blood cells, at least as far as the expression of particular differentiation markers was concerned.
As loss of AVEN in the analyzed tissues did not affect the viability of mice and did not produce any other obvious phenotype, the exact role of AVEN that is essential for embryo survival remains to be identified.
To study the oncogenic potential of AVEN, I investigated the role of AVEN in a mouse model for breast carcinogenesis. While AVEN expression seemed to be increased in breast tumors, tumor onset and progression were not altered in mice with depleted AVEN expression in the mammary gland. Consistently, Aven knockout tumor cells were neither less proliferative nor more prone to undergo apoptosis than Aven wildtype tumor cells. Cell culture experiments demonstrated that AVEN expression is upregulated by estrogen. Knockdown of AVEN in the breast cancer cell line MCF-7 slightly increased UV irradiation-induced apoptosis and accelerated metabolism. So while AVEN does not promote development or progression of breast tumors, enhanced AVEN expression in ER+ breast cancers might contribute to chemotherapy resistance.
To study the physiological role of FUBP1, I generated a conditional Fubp1 knockout mouse model. While the insertion of loxP sites into the Fubp1 locus was occasionally embryonic lethal, some mice with a cell type-specific deletion of Fubp1 in hematopoietic cells or EPO receptor expressing cells were born alive. In these mice, frequencies of hematopoietic stem and progenitor cells as well as erythrocytes were unaltered. These results conflict with previous publications. However, compensating mechanisms might be responsible for the discrepancies between the observed phenotypes and reported FUBP1 function.
In cell culture studies, I could demonstrate that the previously reported upstream regulation of FUBP1 by TAL1 depended on an intact GATA motif in the FUBP1 promoter and that binding of GATA1 to the FUBP1 promoter increased during erythropoiesis.
To identify new FUBP1 target genes with relevance for erythropoiesis, I performed differential gene expression analysis in cells with wildtype and depleted FUBP1 expression. RNA-sequencing and PCR-arrays revealed only moderate differences in the expression of genes that are components of the EPO receptor signaling pathway as well as genes associated with apoptosis and proliferation of hematopoietic cells. By regulating the transcription of these genes, FUBP1 could contribute to efficient erythropoiesis.
Fas Ligand (FasL; CD95L; CD178; TNSF6) is a 40 kDa glycosylated type II transmembrane protein with 279 aa in mice and 281 aa in humans that belongs to the tumor necrosis factor (TNF) family. The extracellular domain (ECD) harbors a TNF homology domain, the receptor binding site, a motif for self assembly and trimerization, and several putative N-glycosylation and a metalloprotease cleavage site/s. The cytoplasmic tail of FasL is the longest of all TNFL family members and contains several conserved signaling motifs, such as a putative tandem Casein kinase I phosphorylation site, a unique proline-rich domain (PRD) and phosphorylatable tyrosine residues (Y7 in mice; Y7, Y9, Y13 in human). The FasL/Fas system is renowned for the potent induction of apoptosis in the receptor-bearing cell and is especially important for immune system functions. It is involved in the killing of target cells by natural killer (NK) and cytotoxic T cells, in the (self) elimination of effector cells following the proliferative phase of an immune response (activation-induced cell death; AICD), in the maintenance of immuneprivileged sites and in the induction and maintenance of peripheral tolerance. Owing to its potent pro-apoptotic signaling capacity and important functions, FasL expression and activity are tightly regulated at transcriptional and posttranscriptional levels and restricted to few cell types, such as immune effector cells and cells of immune-privileged sites. In contrast, Fas is expressed in a variety of tissues including lymphoid tissues, liver, heart, kidney, pancreas, brain and ovary. In addition to its pro-apoptotic function, the FasL/Fas system can also elicit nonapoptotic signals in the receptor-expressing cell. Among others, Fas-signaling exerts co-stimulatory functions in the immune system, e.g. by promoting survival, activation and proliferation of T cells. Besides the capacity to deliver a signal into receptor-bearing cells (‘forward signal’), FasL can receive and transmit signals into the ligand-expressing cell. This phenomenon has been described for several TNF family ligands and is known as ‘reverse signaling’. The first evidence for the existence of reverse signaling into FasL-bearing cells stems from two studies that demonstrated either co-stimulation of murine CD8+ T cell lines by FasL cross-linking or inhibition of activation-induced proliferation of murine CD4+ T cells. In both cases, the observed changes of proliferative behaviour critically depended on the presence of a signaling-competent FasL. Almost certainly, the FasL ICD is functionally involved in signal-transmission: (i) The ICD is highly conserved across species and harbors several signaling motifs, most notably a unique PRD. (ii) Numerous proteins have been identified which interact with the FasL PRD via their SH3 or WW domains and regulate various aspects of FasL biology, such as FasL sorting, storage, cell surface expression and the linkage of FasL to intracellular signaling pathways. (iii) Post-translational modifications of the ICD have been implicated in the sorting of FasL to vesicles and the FasL-dependent activation of Nuclear factor of activated T cells (NFAT). (iv) Proteolytic processing of FasL liberates the ICD and allows its translocation into the nucleus where it might influence gene transcription. (v) It could be shown that overexpression of the FasL ICD is sufficient to initiate reverse signaling upon concomitant T cell receptor (TCR) stimulation and ICD cross-linking. Conflicting data on the consequences of FasL reverse signaling exist, and costimulatory as well as inhibitory functions have been reported. These discrepancies probably reflect the use of artificial experimental systems. Neither the precise molecular mechanism underlying FasL reverse signaling, nor its physiological relevance have been addressed at the endogenous protein level in vivo. Therefore, a ‘knockout/knockin’ mouse model in which wildtype FasL was replaced with a deletion mutant lacking the intracellular portion (FasL Delta Intra) was established in the group of PD Dr. Martin Zörnig. In the present study, FasL Delta Intra mice were phenotypically characterized and were employed to investigate the physiological consequences of FasL reverse signaling at the molecular and cellular level. To ensure that FasL Delta Intra mice represent a suitable model to study the consequences of FasL reverse signaling, we demonstrated that activated lymphocytes from homozygous FasL Delta Intra or wildtype mice express comparable amounts of (truncated) FasL at the cell surface. The truncated protein retains the capacity to induce apoptosis in Fas receptor-positive target cells, as co-culture assays with FasL-expressing activated lymphocytes and Fas-sensitive target cells showed. Additionally, systematic screening of unchallenged mice did not reveal any phenotypic abnormalities. Notably, signs of a lymphoproliferative autoimmune disease associated with FasL-deficiency could not be detected. As several reports have implicated FasL reverse signaling in the regulation of T cell expansion and activation, proliferation of lymphocytes isolated from FasL Delta Intra and wildtype mice in response to antigen receptor stimulation was investigated. Using CFSE dilution assays it could be demonstrated that the proliferative response of CD4+ T cells, CD8+ T cells and of B cells was enhanced in the absence of the FasL ICD. Interestingly, this effect was most pronounced in B cells and could only be detected in CD4+ T cells after depletion of CD4+CD25+ regulatory T cells. To our Summary knowledge, this is the first time that FasL reverse signaling has been demonstrated in B cells. In a series of experiments, the activation of several pathways that are known to play important roles in signal-transmission initiated upon antigen receptor triggering was assessed. As a molecular correlate for the observed enhancement of activation-induced proliferation, Extracellular signal regulated kinase (ERK1/2) phosphorylation was significantly increased in FasL Delta Intra mice following antigen receptor crosslinking. Surprisingly, B cell stimulation lead to a comparable extent of activating phosphorylations on S38 in c-Raf and S218/S222 in MEK1/2 in cells isolated from wildtype and FasL Delta Intra mice, indicating that Mitogen activated protein kinases (MAPKs) upstream of ERK1/2 (Raf-1 and MEK1/2) apparently do not contribute to the differential regulation of ERK1/2. Experiments in which activation-induced Akt phosphorylation (S473) was quantified also did not suggest a participation of Phosphoinositol specific kinase 3 (PI3K)/Akt signals in this process. Instead, further characterization of the upstream pathway revealed an involvement of Phospholipase C gamma (PLC gamma) and Protein kinase C (PKC) signals in FasL-dependent ERK1/2- regulation. Previous studies in our group revealed a Notch-like processing of FasL, resulting in the transcriptional regulation of a reporter gene. Furthermore, an interaction of the FasL ICD with the transcription factor Lymphoid-enhancer binding factor-1 (Lef-1) that affected Lef-1-dependent reporter gene transcription could be demonstrated. Therefore, a molecular analysis of activated lymphocytes was performed to identify FasL reverse signaling target genes. The differential expression of promising candidates was verified by quantitative real-time PCR (qRT-PCR), which showed that the transcription of genes associated with lymphocyte proliferation and activation was increased in FasL Delta Intra mice compared to wildtype mice. Interestingly, an extensive regulation of Lef-1-dependent Wnt/beta-Catenin signalingrelated genes was found. Lef-1 mRNA (RT-PCR) and protein (intracellular FACS staining) could be detected in mature B cells, suggesting the possibility of FasL ICD-mediated inhibition of Lef-1-dependent gene expression in these cells, initiated by Notch-like processing of FasL. To investigate the consequences of FasL reverse signaling in vivo, a potential participation of the FasL ICD in the regulation of immune responses upon various challenges was analyzed. In experiments in which thymocyte proliferation or the expansion of antigen-specific T cells following a challenge with the superantigen Staphylococcus enterotoxin B (SEB), with Lymphocytic choriomeningitis virus (LCMV) or with Listeria monocytogenes were investigated, comparable results were obtained with wildtype and FasL Delta Intra mice. Likewise, the recruitment of neutrophils in a thioglycollate-induced model of peritonitis was not affected by deletion of the FasL ICD. These findings might reflect regulatory mechanisms operating in vivo, such as control exerted by regulatory T cells. Along these lines, proliferative differences in CD4+ T cells could only be detected ex vivo after depletion of CD4+CD25+ regulatory T cells. Furthermore, several in vitro studies indicate that retrograde FasL signals can be observed under conditions of suboptimal lymphocyte stimulation, but not when the TCR is optimally stimulated. Therefore, the potent initiation of antigen receptor signaling by stimuli like SEB or LCMV might have masked inhibitory FasL reverse signaling in these experiments. In agreement with the observed hyperactivation of lymphocytes in the absence of the ICD ex vivo, the increase in germinal center B cells (GCs) following immunization with the hapten 3-hydroxy 4-nitrophenylacetyl (NP) and the number of antibody-secreting PCs was significantly higher in FasL Delta Intra mice. The larger quantity of PCs correlated with increased titers of NP-binding, i.e. antigen-specific, IgM and IgG1 antibodies in the serum of FasL Delta Intra mice after immunization. These data suggest that FasL reverse signaling exerts immunmodulatory functions. Supporting this notion, a model of Ovalbumin-induced allergic airway inflammation revealed an involvement of retrograde FasL-signals in the recruitment of immune effector cells into the lung and in the activation of T cells following exposure of mice to Ovalbumin. Together, our ex vivo and in vivo findings based on endogenous FasL protein levels demonstrate that FasL ICD-mediated reverse signaling is a negative modulator of certain immune responses. It is tempting to speculate that FasL reverse signaling might be a fine-tuning mechanism to prevent autoimmune diseases, a theory which will be tested in adequate mouse models in the future.
Der programmierte Zelltod (Apoptose) ist ein wichtiger Mechanismus zur Eliminierung von beschädigtem Gewebe und entarteten Zellen. Die Deregulierung der Apoptose führt zu zahlreichen Erkrankungen wie neuro-degenerativen Störungen und Krebs. Insbesondere in Tumoren wird der programmierte Zelltod mit Hilfe von hochregulierten, anti-apoptotischen Proteinen umgangen und es entstehen Resistenzen gegen Chemotherapien. Um innovative therapeutische Ansätze zu finden, wurden in diesem Projekt mit Hilfe eines Hefe-Survival-Screens neue, potentiell anti-apoptotische Proteine im Pankreaskarzinom identifiziert. Von den insgesamt 38 identifizierten Genprodukten wurden zwei für eine weiterführende Analyse ausgewählt.
Eins der näher untersuchten Proteine ist die Pyruvoyl-tetrahydrobiopterin-Synthase (PTS), ein wichtiges Enzym für die Biosynthese von Tetrahydrobiopterin (BH4). BH4 ist ein Kofaktor, der von mehreren Enzymen der Zelle für ihre Funktionen benötigt wird. In Zellkultur-Experimenten konnte gezeigt werden, dass eine Überexpression von PTS die Zellen vor Apoptose schützen kann, während eine Herunterregulation durch genetischen knockdown die Zellen gegenüber Apoptose-Stimuli sensibilisiert und ihr Wachstum beeinträchtigt. In Xenograft-Experimenten mit NOD/SCID-Mäusen konnte zudem gezeigt werden, dass Tumore mit einem PTS-Knockdown signifikant langsamer wachsen als die der Kontrollgruppe. Zusammengenommen deuten diese Ergebnisse auf eine Rolle von PTS bei der Apoptose-Regulation und beim Tumorwachstum hin, was das Protein zu einem attraktiven Target für die Krebstherapie macht.
Als zweites wurde ein Protein analysiert, das eine Untereinheit des respiratorischen Komplex I bildet: NDUFB5 (NADH-Dehydrogenase 1 beta Subcomplex, 5). Das besondere an diesem Protein sind die verschiedenen Isoformen, die durch alternatives Splicing zustandekommen. Eine Isoform, der die Exone 2 und 3 fehlen, wurde im Hefe-Survival-Screen identifiziert. Bei Überexpression in Zelllinien konnte sie im Gegensatz zum Volllänge-Protein die Apoptoserate reduzieren. Und auch Ergebnisse aus Versuchen mit Isoformen-spezifischem knockdown deuten an, dass hauptsächlich die verkürzte Isoform sNDUFB5 für die Regulation von Apoptose und Proliferation verantwortlich ist. Diese Beobachtungen konnten mit denselben Zellen im Xenograft-Tiermodell jedoch nicht bestätigt werden. Die Ursachen dafür blieben unklar. Zusätzlich wurden immunhistochemische Analysen von Pankreaskarzinomen und normalem Pankreasgewebe durchgeführt. Sie ergaben, dass die kurze Isoform sNDUFB5 im Tumor stark überexpremiert ist, während die Expression des Volllänge-Proteins in normalem und Tumorgewebe ähnlich hoch ausfällt. Dieser Befund macht NDUFB5 zu einem interessanten therapeutischen Target.
Die näher untersuchten Kandidaten-Gene zeigen beide Potential als neue Angriffspunkte für eine molekulare Krebstherapie. Andere in dem Hefe-Survival-Screen identifizierte Proteine wurden bereits als anti-apoptotisch und/oder in Krebszellen überexprimiert beschrieben. Diese Ergebnisse demonstrieren, dass ein funktionelles, Hefe-basiertes Screeningsystem geeignet ist, neue bisher unbekannte Proteine mit anti-apoptotischer Funktion zu identifizieren. Auch zeigen die Befunde, dass bereits bekannte Proteine weitere bisher unbekannte Funktionen wie z.B. die Inhibition von Apoptose aufweisen können. Basierend auf solchen mehrfachen Proteinfunktionen lassen sich weitere therapeutische Möglichkeiten ableiten.
Embryonale Stammzellen (ESCs) sind ein wichtiges Werkzeug zur Untersuchung der frühen embryonalen Entwicklung. ESCs können mit Hilfe neuer Technologien zur Modifikation von Genen (z.B. mit dem CRISPR/Cas9 System) genetisch manipuliert werden. Daraus resultierende „knockout“ ES Zelllinien können helfen, die physiologische Rolle von Proteinen während der Differenzierung zu verstehen.
Transkriptionsfaktoren, die schnell und spezifisch Signalwege regulieren, spielen während der Embryonalentwicklung und während der Differenzierung von ESCs in vielen verschiedenen Zelltypen eine essentielle Rolle. Der Transkriptionsregulator „Far Upstream Binding Protein 1“ (FUBP1) ist ein Protein, welches eine ganz bestimmte einzelsträngige DNA Sequenz, das „Far Upstream Sequenz Element“, erkennt, bindet, und dadurch Gene wie z.B c-myc oder p21 reguliert. Mit der Entwicklung zweier Fubp1 Genfallen Mausstämme (Fubp1 GT) sollte die Frage nach der physiologischen Funktion von FUBP1 beantwortet werden. Die homozygoten FUBP1-defizienten GT Embryonen sterben im Mutterleib ungefähr am Tag E15.5 der Embryonalentwicklung. Sie sind kleiner als Wildtypembryonen und zeigen ein anämisches Aussehen. Daher wurden diese Mausmodelle hinsichtlich der Hämatopoese untersucht, die zu diesem Zeitpunkt vor allem in der Leber stattfindet. Es konnte eine signifikante Reduktion der hämatopoetischen Stammzellen (HSCs) festgestellt werden und zusätzlich war die langfristige Repopulation der FUBP1-/--Stammzellen im Knochenmark in Transplantationsexperimenten reduziert.
In der vorliegenden Arbeit wurde die Rolle von FUBP1 in einem weiteren Stammzellsystem analysiert und gleichzeitig seine Bedeutung in anderen Zelltypen der frühen Embryonalentwicklung untersucht.
Die Quantifizierung der FUBP1 Expression in den ESCs und während der Differenzierung zu sogenannten `embryoid bodies` (EBs) zeigten eine starke Expression auf mRNA- und auf Proteinebene. Nach der erfolgreichen Optimierung der Differenzierung von murinen ESCs wurden Fubp1 „knockout“ (KO) ESC Klone mit Hilfe der CRISPR/Cas9 Technologie etabliert. Die molekularbiologische Analyse der ESCs zeigte eine signifikante Erhöhung der Oct4 mRNA-Expression, während Nanog und die Differenzierungsmarker Brachyury, Nestin und Sox17 unverändert und in vergleichbarer Menge zu den Kontrollen vorhanden waren. Während der Differenzierung der Fubp1 KO Klone zu EBs zeigte sich eine signifikante Reduktion mesodermaler Marker wie Flk-1, SnaiI, Snai2, Bmp4 und FgfR2. Mit Hilfe durchflusszytometrischer Analysen bestätigte sich die verzögerte Bildung mesodermaler Zellen (Brachyury- und Flk-1-exprimierender Zellen) in den Fubp1 KO Klonen der EBs an den Tagen 3, 4 und 5 nach Beginn der Differenzierung.
Die Anwendung einer Ko-Kultivierung auf OP9 Zellen zur Differenzierung der ESCs in hämatopoetische Linien sollte zeigen, ob der Fubp1 KO ESCs ein Defekt in der frühen Entwicklung hämatopoetischer Stammzellen zu beobachten ist. Erneut konnte am Tag 5 der ESC-Differenzierung in der OP9 Ko-Kultur eine signifikante Reduktion der mesodermalen (Flk-1+) Zellen festgestellt werden. Die weitere Differenzierung zu hämatopoetischen CD45+ Zellen zeigte jedoch keinen Unterschied im prozentualen Anteil CD45+ Zellen am Tag 12 der Differenzierung. Auch die gezielte Differenzierung zu erythroiden Zellen durch Zugabe des Zytokins EPO zum Medium zeigte keinen signifikanten Unterschied im Differenzierungsgrad der erythroiden Zellen zwischen Kontroll- und Fubp1 KO Klonen.
In weiteren Experimenten habe ich in dieser Arbeit die Expression von FUBP1 in WT Embryos an den Tagen E9.5 und E13.5 der Embryonalentwicklung untersucht. Hierbei zeigte sich in beiden Entwicklungsstadien eine immunhistochemische Anfärbung von FUBP1 in den meisten Zellen des Embryos. Die Annahme, dass die Abwesenheit von FUBP1 in der Embryonalentwicklung zu verstärkten apoptotischen Vorgängen führen könnte und gleichzeitig die massive Expansion von Zellen gestört sein könnte wurde mit Hilfe immunhistochemischer Färbung von „cleaved Caspase 3“ (Apoptosemarker) und „Ki-67“ (Proliferationsmarker) in den homozygoten Fubp1 GT Embryos an den Tagen E9.5 und E13.5 nicht bestätigt.
Die Ergebnisse dieser Arbeit lassen darauf schließen, dass die Regulation von Apoptose und Proliferation durch FUBP1 während der Embryonalentwicklung nicht die Hauptrolle von FUBP1 darstellt. Es zeigte sich jedoch, dass FUBP1 als Transkriptionsregulator wichtig für die mesodermale Differenzierung von ESCs ist. Zu beobachten war, dass es in den FUBP1-defizienten ESCs zu einer Verzögerung der mesodermalen Differenzierung kommt. Es konnte bereits gezeigt werden, dass FUBP1 essenziell für die Selbsterneuerung von HSCs ist. Dies macht deutlich, dass FUBP1 neben der Proliferation und Apoptose ein breiteres Spektrum an Signalwegen reguliert, die für Stammzellen und deren Differenzierung von Bedeutung sind.